Sanofi (NASDAQ:SNY) Coverage Initiated at The Goldman Sachs Group

The Goldman Sachs Group started coverage on shares of Sanofi (NASDAQ:SNY) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The firm issued a neutral rating and a $65.00 target price on the stock.

Other research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Stock Performance

Shares of SNY opened at $56.90 on Friday. The company has a market capitalization of $144.40 billion, a PE ratio of 22.85, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a one year low of $45.22 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company’s fifty day moving average price is $54.55 and its 200 day moving average price is $52.85.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Institutional Trading of Sanofi

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Synergy Asset Management LLC bought a new stake in Sanofi in the fourth quarter valued at about $25,000. McClarren Financial Advisors Inc. boosted its position in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after buying an additional 543 shares in the last quarter. Lee Danner & Bass Inc. acquired a new position in Sanofi in the fourth quarter valued at about $31,000. Bessemer Group Inc. boosted its position in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock valued at $32,000 after buying an additional 242 shares in the last quarter. Finally, Sunbelt Securities Inc. boosted its position in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.